Metoprolol succinate

Research use only, not for human use.

A selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension.

A selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension.Hypertension Approved(In Vitro):Metoprolol (0-1000 μg/mL; 24-72 h) shows cytotoxic effect on U937 and MOLT-4 cells dose and time dependently.(In Vivo):Metoprolol (2.5 mg/kg/h; infusion; 11 weeks) reduces proinflammatory cytokines and atherosclerosis in ApoE?/? Mice.Metoprolol (15 mg/kg/q12h; i.g.; 5 days) shows anti-inflammation and anti-virus effects in murine model with coxsackievirus B3-induced viral myocarditis.Metoprolol (2.5 mg/kg; i.v.; 3 bolus injections) significantly decreased activated caspase-9 protein expression and inhibits myocardial apoptosis in coronary microembolization (CME) rats.

Metoprolol (0-1000 μg/mL; 24-72 h) shows cytotoxic effect on U937 and MOLT-4 cells dose and time dependently.Cell Cytotoxicity Assay Cell Line:U937 and MOLT-4 cells Concentration:1, 10, 50, 100, 500 and 1000 μg/mL Incubation Time:24, 48 and 72 h Result:Significantly decreased the viability of U937 and MOLT-4 cells at 1000 μg/mL (3740.14μM) concentration after 48 hours incubation time, significantly reduced the viability of U937 cells at ≥500 μg/ml (≥1870.07μM) concentrations after 72 hours incubation time, and significantly decreased the viability of MOLT4 cells at ≥100 μg/ml (≥374.01μM) concentrations after 72 hours incubation.

Metoprolol (2.5 mg/kg/h; infusion; 11 weeks) reduces proinflammatory cytokines and atherosclerosis in ApoE?/? Mice.Metoprolol (15 mg/kg/q12h; i.g.; 5 days) shows anti-inflammation and anti-virus effects in murine model with coxsackievirus B3-induced viral myocarditis.Metoprolol (2.5 mg/kg; i.v.; 3 bolus injections) significantly decreased activated caspase-9 protein expression and inhibits myocardial apoptosis in coronary microembolization (CME) rats. Animal Model:Male ApoE?/? mice Dosage:2.5?mg/kg/h Administration:Via osmotic minipumps, 11 weeks Result:Significantly reduced atherosclerotic plaque area in thoracic aorta, reduced serum TNFα and the chemokine CXCL1 as well as decreasing the macrophage content in the plaques.Animal Model:Balb/c mice, coxsackievirus B3 (CVB3) induced viral myocarditis (VMC) model Dosage:15 mg/kg/q12h Administration:Oral gavage, 5 consecutive days Result:Reduced pathological scores of VMC induced by CVB3 infection, protected the myocardium against viral damage by reducing serum cTn-I levels. Decreased the levels of myocardial pro-inflammatory cytokines and increase the expression of anti-inflammatory cytokine. Significantly decreased myocardial virus titers.

——

GPCR/G Protein

Adrenergic Receptor

β1-adrenergicreceptor

Cardiovascular Disease

Hypertension

98418-47-4

652.8159

C34H56N2O10

>98% (HPLC)

10 mM in DMSO

CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.C(CC(=O)O)C(=O)O

Butanedioic acid, compd. with 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol (1:2)

(-20℃)

With Ice Pack

≥ 2 years